The Cumulative Risk to Human Health of Pharmaceuticals in New Jersey Surface Water

REFERENCES

• Alvarez DA, Stackelberg PE, Petty JD, et al. 2005. Comparison of a novel passive sampler to standard water-column sampling for organic contaminants associated with wastewater effluents entering a New Jersey stream. Chemosphere 61:610–22
   PubMed Web of Science ®Google Scholar
• American Water. 2011. Annual Water Quality Report—New Jersey. Available at http://www.amwater.com/njaw/About-Us/Corporate-Information/ (accessed August 2012)
   Google Scholar
• AWWARF (American Water Works Association Research Foundation). 2008. Toxicological Relevance of EDCs and Pharmaceuticals in Drinking Water. Denver, CO, USA
   Google Scholar
• Bercu JP, Parke NJ, Fiori JM, et al. 2008. Human health risk assessments for three neuropharmaceutical compounds in surface waters. Regul Toxicol Pharmacol 50:420–7
   PubMed Web of Science ®Google Scholar
• Blanset DL, Zhang J, and Robson MG. 2007. Probabilistic estimates of lifetime daily doses from consumption of drinking water containing trace levels of N,N-diethyl-meta-toluamide (DEET), triclosan, or acetaminophen and the associated risk to human health. Hum Ecol Risk Assess 13:615–31
   Web of Science ®Google Scholar
• Bogen KT, Cullen AC, Frey HC, et al. 2009. Probabilistic exposure analysis for chemical risk characterization. Toxicol Sci 109:4–17
   PubMed Web of Science ®Google Scholar
• Borgert CJ, Sargent EV, Casella G, et al. 2012. The human relevant potency threshold: reducing uncertainty by human calibration of cumulative risk assessments. Regul Toxicol Pharmacol 62:313–28
   PubMed Web of Science ®Google Scholar
• Brooks BW, Huggett DB, and Boxall ABA. 2009. Pharmaceuticals and personal care products: Research needs for the next decade. Environ Toxicol Chem 28:2469–72
   PubMed Web of Science ®Google Scholar
• Bull RJ, Crook J, Whittaker M, et al. 2011. Therapeutic dose as the point of departure in assessing potential health hazards from drugs in drinking water and recycled municipal wastewater. Regul Toxicol Pharmacol 60:1–19
   PubMed Web of Science ®Google Scholar
• Cunningham VL, Perino C, D’Aco VJ, et al. 2010. Human health risk assessment of carbamazepine in surface waters of North America and Europe. Regul Toxicol Pharmacol 56:343–51
   PubMed Web of Science ®Google Scholar
• Daughton CG and Jones-Lepp TL. (eds) 2001. Pharmaceuticals and Personal Care Products in the Environmental: Scientific and Regulatory Issues. American Chemical Society, Washington, DC, USA
   Google Scholar
• Daughton CG and Ruhoy IS. 2009. Environmental footprint of pharmaceuticals: The significance of factors beyond direct excretion to sewers. Environ Toxicol Chem 28:2495–521
   PubMed Web of Science ®Google Scholar
• de Jongh CM, Kooij PJF, de Voogt P, et al. 2012. Screening and human health risk assessment of pharmaceuticals and their transformation products in Dutch surface waters and drinking water. Sci Total Environ 427–428:70–7
   PubMed Web of Science ®Google Scholar
• Dolan DG, Naumann BD, Sargent EV, et al. 2005. Application of the threshold of toxicological concern concept to pharmaceutical manufacturing operations. Regul Toxicol Pharmacol 43:1–9
   PubMed Web of Science ®Google Scholar
• DIC (Drug Interactions Checker). 2011. Available at http://www.drugs.com/drug_interactions.html (accessed May 2011)
   Google Scholar
• Ferrari B, Paxéus N, Giudice RL, et al. 2003. Ecotoxicological impact of pharmaceuticals found in treated wastewaters: study of carbamazepine, clofibric acid, and diclofenac. Ecotoxicol Environ Saf 55:359–70
   PubMed Web of Science ®Google Scholar
• Fischer JM. 2011. Unpublished Data from 2001 Synoptic Survey of 30 Streams in New Jersey. Written Communications USGS (United States Geological Survey) Trenton, NJ, USA
   Google Scholar
• Focazio MJ, Kolpin DW, Barnes KK, et al. 2008. A national reconnaissance for pharmaceuticals and other organic wastewater contaminants in the United States—II) Untreated drinking water sources. Sci Total Environ 402:201–16
   PubMed Web of Science ®Google Scholar
• ECOS (Environmental Council of the States). 2010. State Experiences with Emerging Contaminants: Recommendations for Federal Action, Washington, DC, USA
   Google Scholar
• Kolpin DW, Furlong ET, Meyer MT, et al. 2002. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999–2000: A national reconnaissance. Environ Sci Technol 36:1202–11
   PubMed Web of Science ®Google Scholar
• Kumar A and Xagoraraki I. 2010. Human health risk assessment of pharmaceuticals in water: An uncertainty analysis for meprobamate, carbamazepine, and phenytoin. Regul Toxicol Pharmacol 57:146–56
   PubMed Web of Science ®Google Scholar
• Mao J, Mohutsky MA, Harrelson JP, et al. 2011. Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma. Drug Metab Dispos 39:591–602
   PubMed Web of Science ®Google Scholar
• Mao J, Mohutsky MA, Harrelson JP, et al. 2012. Predictions of cytochrome p450-mediated drug-drug interactions using cryopreserved human hepatocytes: Comparison of plasma and protein-free media incubation conditions. Drug Metab Dispos 40:706–16
   PubMed Web of Science ®Google Scholar
• Naumann BD and Sargent EV. 1997. Setting occupational exposure limits for pharmaceuticals. Occup Med 12:67–80
   PubMedGoogle Scholar
• Pomati F, Orlandi C, Clerici M, et al. 2008. Effects and Interactions in an Environmentally Relevant Mixture of Pharmaceuticals. Toxicol Sci 102:129–37
   PubMed Web of Science ®Google Scholar
• Post GB, Louis JB, Cooper KR, et al. 2009. Occurrence and potential significance of perfluorooctanoic acid (pfoa) detected in New Jersey public drinking water systems. Environ Sci Technol 43:4547–54
   PubMed Web of Science ®Google Scholar
• Richardson SD. 2009. Water Analysis: Emerging contaminants and current issues. Anal Chem 81:4645–77
   PubMed Web of Science ®Google Scholar
• Roden NM, Sargent EV, Hong JY, et al. 2013. The Cumulative Risk of Pharmaceuticals in New Jersey Surface Water to Human Health. Doctoral Dissertation. University of Medicine and Dentistry of New Jersey, Piscataway NJ, USA
   Google Scholar
• Sargent EV, Faria E, Pfister T, et al. 2013. Guidance on the establishment of acceptable daily exposure limits (ADE) to support risk-based manufacture of pharmaceutical products. Regul Toxicol Pharmacol 65:242–50
   PubMed Web of Science ®Google Scholar
• Schwab BW, Hayes EP, Fiori JM, et al. 2005. Human pharmaceuticals in US surface waters: A human health risk assessment. Regul Toxicol Pharmacol 42:296–312
   PubMed Web of Science ®Google Scholar
• Teuschler LK 2007. Deciding which chemical mixtures risk assessment methods work best for what mixtures. Toxicol Appl Pharmacol 223:139–47
   PubMed Web of Science ®Google Scholar
• USEPA (US Environmental Protection Agency). 1997. Exposure Factors Handbook. EPA/600/P-95/002F. Office of Research and Development, Washington, DC, USA
   Google Scholar
• USEPA. 2000a. Methodology for Deriving Ambient Water Quality Criteria for the Protection of Human Health. EPA/822/B-00/004. Office of Water, Washington, DC, USA
   Google Scholar
• USEPA. 2000b. Supplementary Guidance for Conducting Health Risk Assessment of Chemical Mixtures. EPA/630/R-00/002. Office of Research and Development, Washington, DC, USA
   Google Scholar
• USEPA. 2003. Framework for Cumulative Risk Assessment. EPA/630/P-02/001F. Risk Assessment Forum, Washington, DC, USA
   Google Scholar
• USEPA. 2007. Concepts, Methods, and Data Sources for Cumulative Health Risk Assessment of Multiple Chemicals, Exposures and Effects: A Resource Document. EPA/600/R-06/013F. Office of Research and Development, Washington, DC, USA
   Google Scholar
• USEPA. 2011. Exposure Factors Handbook. EPA/600/R-090/052F. Office of Research and Development, Washington, DC, USA
   Google Scholar
• USFDA (US Food and Drug Administration) 2012. Draft: Guidance for Industry: Drug Interaction Studies—Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Center for Drug Evaluation and Research, Washington, DC, USA
   Google Scholar
• USGAO (US Government Accountability Office). 2011. Environmental Health: Action Needed to Sustain Agencies’ Collaboration on Pharmaceuticals in Drinking Water. GAO-11-346. Washington, DC, USA
   Google Scholar
• Waiser MJ, Tumber V, and Holm J. 2011. Effluent-dominated streams. Part 1: Presence and effects of excess nitrogen and phosphorus in Wascana Creek, Saskatchewan, Canada. Environ Toxicol Chem 30:496–507
   PubMed Web of Science ®Google Scholar
• Webb SF. 2001. A data based perspective on the environmental risk assessment of human pharmaceuticals iii—Indirect human exposure. In: Kummerer K (ed), Pharmaceuticals in the Environment: Sources, Fate, Effects and Risks. Springer, Berlin, Germany
   Google Scholar
• Webb S, Ternes T, Gibert M, et al. 2003. Indirect human exposure to pharmaceuticals via drinking water. Toxicol Lett 142:157–67
   PubMed Web of Science ®Google Scholar
• WHO (World Health Organization). 2011. Pharmaceuticals in Drinking-water. WHO/HSE/WSH/11.05. Geneva, Switzerland
   Google Scholar
• Williams RT (ed). 2005. Human Pharmaceuticals—Assessing the impact on aquatic ecosystems. Society of Environmental Toxicology and Chemistry (SETAC). Pensacola, FL, USA
   Google Scholar